Nicolas Wentzensen

List of Publications by Year
in descending order

292	18,689	13087 68	17580 121
papers	citations	h-index	g-index

297	297	297	20112
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics and Gynecology, 2013, 121, 829-846.	1.2	617
2	Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2016, 2, 16086.	18.1	615
3	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	0.8	613
4	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 102-131.	0.9	608
5	Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 368-383.	3.0	583
6	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
7	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	7.7	478
8	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecologic Oncology, 2015, 136, 178-182.	0.6	374
9	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
10	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	0.8	349
11	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	9.4	294
12	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute, 2014, 106, .	3.0	255
13	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute, 2019, 111, 923-932.	3.0	249
14	Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecologic Oncology, 2009, 112, 293-299.	0.6	247
15	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	1.6	236
16	Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. JAMA Internal Medicine, 2018, 178, 1210.	2.6	233
17	Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2536-2545.	1.1	224
18	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 553-560.	1.1	223

#	Article	IF	Citations
19	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
20	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	13.5	221
21	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	3.0	200
22	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3255-64.	3.3	197
23	Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. Clinical Cancer Research, 2012, 18, 4154-4162.	3.2	196
24	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	5.8	188
25	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
26	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
27	Biomarkers in Cervical Cancer Screening. Disease Markers, 2007, 23, 315-330.	0.6	175
28	Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. Journal of Clinical Oncology, 2019, 37, 1895-1908.	0.8	169
29	Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. International Journal of Cancer, 2009, 125, 2151-2158.	2.3	165
30	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
31	Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. Journal of Clinical Oncology, 2015, 33, 83-89.	0.8	156
32	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. Journal of the National Cancer Institute, 2016, 108, djw100.	3.0	147
33	Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2125-2137.	1.1	143
34	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute, 2015, 107, djv257.	3.0	130
35	Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene, 2002, 21, 419-426.	2.6	126
36	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2021, 385, 1908-1918.	13.9	125

#	Article	IF	Citations
37	Eurogin roadmap 2017: Triage strategies for the management of <scp>HPV</scp>â€positive women in cervical screening programs. International Journal of Cancer, 2018, 143, 735-745.	2.3	124
38	Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. Journal of the National Cancer Institute, 2012, 104, 1738-1749.	3.0	119
39	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	3.0	116
40	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	0.9	116
41	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	2.8	116
42	Genomic characterization of viral integration sites in HPVâ€related cancers. International Journal of Cancer, 2016, 139, 2001-2011.	2.3	113
43	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
44	Metabolic Syndrome and Risk of Endometrial Cancer in the United States: A Study in the SEERâ€“Medicare Linked Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 261-267.	1.1	109
45	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 2020, 22, 100293.	3.2	109
46	Defining the genetic susceptibility to cervical neoplasiaâ€”A genome-wide association study. PLoS Genetics, 2017, 13, e1006866.	1.5	105
47	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	2.6	101
48	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Internal Medicine, 2019, 179, 881.	2.6	98
49	Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2016, 213, 1444-1454.	1.9	96
50	Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer, 2005, 105, 461-467.	2.0	95
51	How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer, 2009, 125, 2489-2496.	2.3	91
52	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
53	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	0.8	88
54	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	5.8	86

#	Article	IF	Citations
55	Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes. American Journal of Epidemiology, 2013, 177, 142-151.	1.6	84
56	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology, 2014, 135, 297-304.	0.6	83
57	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. International Journal of Cancer, 2017, 140, 2192-2200.	2.3	83
58	Accuracy and Efficiency of Deep-Learningâ€"Based Automation of Dual Stain Cytology in Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 72-79.	3.0	82
59	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2840-2849.	1.1	79
60	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic Oncology, 2015, 137, 14-22.	0.6	79
61	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncology, 2019, 5, 181.	3.4	79
62	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€"ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
63	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29â€‰900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV,the, 2021, 8, e531-e543.	2.1	77
64	Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 113-120.	1.1	76
65	Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. International Journal of Cancer, 2009, 124, 964-969.	2.3	76
66	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology, 2012, 176, 269-278.	1.6	76
67	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1081-1089.	1.1	76
68	Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 3-11.	4.5	75
69	Triage of women with ASCUS and LSIL cytology. Cancer, 2006, 111, 58-66.	2.0	74
70	Strategies for screening and early detection of anal cancers: A narrative and systematic review and metaâ€anal ysis of cytology, HPV testing, and other biomarkers. Cancer Cytopathology, 2018, 126, 447-460.	1.4	72
71	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
72	Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. Journal of Lower Genital Tract Disease, 2017, 21, 216-222.	0.9	71

#	Article	IF	Citations
73	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. Aids, 2012, 26, 2185-2192.	1.0	70
74	p16^{INK4a} immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. Cancer Cytopathology, 2012, 120, 294-307.	1.4	70
75	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
76	A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 2016, 139, 2606-2615.	2.3	68
77	Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. Preventive Medicine, 2021, 151, 106596.	1.6	68
78	2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 90-101.	0.9	66
79	From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development. Cancer Discovery, 2013, 3, 148-157.	7.7	65
80	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	0.8	65
81	Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2015, 19, 91-96.	0.9	64
82	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
83	Discovery and validation of methylation markers for endometrial cancer. International Journal of Cancer, 2014, 135, 1860-1868.	2.3	62
84	Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 819-827.	0.4	62
85	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer, 2017, 141, 701-710.	2.3	62
86	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1052-1060.	1.1	59
87	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	3.0	59
88	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research (Amsterdam,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137	3.5	58
89	Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncology, 2022, 8, 895.	3.4	57
90	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. Journal of Lower Genital Tract Disease, 2017, 21, 230-234.	0.9	56

#	Article	IF	Citations
91	Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. Journal of the National Cancer Institute, 2019, 111, 129-136.	3.0	56
92	Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 261-267.	0.9	55
93	Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses, 2017, 9, 206.	1.5	55
94	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
95	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. Annals of Internal Medicine, 2017, 166, 118.	2.0	53
96	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications, 2020, 11, 886.	5.8	52
97	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. International Journal of Cancer, 2012, 131, 2903-2909.	2.3	51
98	p16INK4a Immunohistochemistry in Cervical Biopsy Specimens. American Journal of Clinical Pathology, 2014, 142, 767-772.	0.4	51
99	Interobserver reproducibility and accuracy of p16/<scp>K</scp>iâ€67 dualâ€stain cytology in cervical cancer screening. Cancer Cytopathology, 2014, 122, 914-920.	1.4	51
100	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. Annals of Internal Medicine, 2018, 168, 20.	2.0	50
101	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Clinical Cancer Research, 2019, 25, 5937-5946.	3.2	50
102	Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. International Journal of Cancer, 2007, 121, 1417-1423.	2.3	49
103	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	0.6	49
104	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
105	Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Research, 2017, 77, 3951-3960.	0.4	48
106	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. International Journal of Cancer, 2017, 140, 600-610.	2.3	48
107	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 144-147.	0.9	48
108	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 648-656.	1.1	47

#	Article	IF	Citations
109	No Evidence for Synergy Between Human Papillomavirus Genotypes for the Risk of High-Grade Squamous Intraepithelial Lesions in a Large Population-Based Study. Journal of Infectious Diseases, 2014, 209, 855-864.	1.9	46
110	A demonstration of automated visual evaluation of cervical images taken with a smartphone camera. International Journal of Cancer, 2020, 147, 2416-2423.	2.3	46
111	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
112	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	1.1	44
113	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viralâ€host interaction with implications for disease intervention. International Journal of Cancer, 2020, 147, 2677-2686.	2.3	44
114	Telomere structure and maintenance gene variants and risk of five cancer types. International Journal of Cancer, 2016, 139, 2655-2670.	2.3	43
115	HPV-based cervical cancer screening- facts, fiction, and misperceptions. Preventive Medicine, 2017, 98, 33-35.	1.6	43
116	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. Journal of the National Cancer Institute, 2019, 111, 137-145.	3.0	43
117	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
118	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis, 2016, 37, 188-196.	1.3	41
119	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 49.	3.8	41
120	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infectious Diseases, 2015, 15, 544.	1.3	40
121	Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Cancer Causes and Control, 2015, 26, 287-296.	0.8	40
122	Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. American Journal of Obstetrics and Gynecology, 2020, 223, 549.e1-549.e13.	0.7	40
123	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
124	Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. British Journal of Cancer, 2021, 124, 831-841.	2.9	39
125	Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer, 2006, 107, 2307-2313.	2.0	38
126	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Research, 2019, 79, 5442-5451.	0.4	36

#	Article	IF	Citations
127	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.4	35
128	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
129	Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes and Control, 2016, 27, 737-748.	0.8	34
130	Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. Journal of Infectious Diseases, 2014, 210, 448-455.	1.9	33
131	Kernel canonical correlation analysis for assessing geneâ€“gene interactions and application to ovarian cancer. European Journal of Human Genetics, 2014, 22, 126-131.	1.4	33
132	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
133	Smoking and subsequent human papillomavirus infection: a mediation analysis. Annals of Epidemiology, 2017, 27, 724-730.e1.	0.9	33
134	Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 189-197.	1.1	33
135	Triage of HPV-positive women in cervical cancer screening. Lancet Oncology, The, 2013, 14, 107-109.	5.1	32
136	PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes and Control, 2015, 26, 1729-1736.	0.8	31
137	Attributing Oncogenic Human Papillomavirus Genotypes to High-grade Cervical Neoplasia. American Journal of Surgical Pathology, 2015, 39, 496-504.	2.1	31
138	Metaâ€analysis of the accuracy of p16 or p16/Kiâ€67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathology, 2019, 127, 169-180.	1.4	31
139	Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016â€“2020. Journal of Women's Health, 2021, 30, 5-13.	1.5	31
140	Metaâ€analysis of agreement/concordance statistics in studies comparing selfâ€vs clinicianâ€collected samples for <scp>HPV</scp> testing in cervical cancer screening. International Journal of Cancer, 2022, 151, 308-312.	2.3	31
141	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Womenâ€™s Health Initiative Observational Study. JNCI Cancer Spectrum, 2019, 3, pkz029.	1.4	30
142	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Archives of Pathology and Laboratory Medicine, 2020, 144, 725-734.	1.2	30
143	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. Journal of Clinical Microbiology, 2014, 52, 2892-2897.	1.8	29
144	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virusâ€“Positive Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 69, 631-638.	2.9	29

#	Article	IF	Citations
145	Heterogeneity of highâ€grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management. International Journal of Cancer, 2013, 132, 148-154.	2.3	28
146	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
147	Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. Journal of the National Cancer Institute, 2018, 110, 750-757.	3.0	28
148	Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing. Journal of Clinical Microbiology, 2019, 57, .	1.8	27
149	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infectious Agents and Cancer, 2020, 15, 60.	1.2	27
150	Human Papillomavirus Load Measured by Linear Array Correlates with Quantitative PCR in Cervical Cytology Specimens. Journal of Clinical Microbiology, 2012, 50, 1564-1570.	1.8	26
151	An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 87-89.	0.9	26
152	Hierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study. Cancer Research, 2010, 70, 8578-8586.	0.4	25
153	Triage of <scp>ASCâ€H</scp>: A metaâ€analysis of the accuracy of highâ€risk <scp>HPV</scp> testing and other markers to detect cervical precancer. Cancer Cytopathology, 2016, 124, 261-272.	1.4	25
154	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
155	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
156	Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. Gynecologic Oncology, 2009, 115, 493-496.	0.6	24
157	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
158	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 42-49.	1.1	23
159	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
160	Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 87-90.	0.9	23
161	A prospective study of risk-based colposcopy demonstrates improved detection of cervicalÂprecancers. American Journal of Obstetrics and Gynecology, 2018, 218, 604.e1-604.e8.	0.7	23
162	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	0.8	23

#	Article	IF	Citations
163	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
164	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
165	Hormone therapy: short-term relief, long-term consequences. Lancet, The, 2015, 385, 1806-1808.	6.3	22
166	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. Obstetrics and Gynecology, 2016, 128, 1248-1257.	1.2	22
167	HLAandKIRAssociations of Cervical Neoplasia. Journal of Infectious Diseases, 2018, 218, 2006-2015.	1.9	22
168	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	0.9	22
169	No Metastatic Cervical Adenocarcinomas in a Series of p16INK4a-Positive Mucinous or Endometrioid Advanced Ovarian Carcinomas. International Journal of Gynecological Pathology, 2008, 27, 18-23.	0.9	21
170	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Womenâ€™s Health Initiative Observational Study. Breast Cancer Research, 2017, 19, 28.	2.2	21
171	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	3.0	21
172	A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significanceâ€“Low-Grade Squamous Intraepithelial Lesion Triage Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1341-1349.	1.1	20
173	Screening for anal cancer: endpoints needed. Lancet Oncology, The, 2012, 13, 438-440.	5.1	20
174	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
175	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	1.1	20
176	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. Journal of the National Cancer Institute, 2019, 111, 820-827.	3.0	20
177	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. Gynecologic Oncology, 2020, 156, 682-688.	0.6	20
178	Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers. Frontiers in Oncology, 2015, 5, 25.	1.3	19
179	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
180	Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have â‰¥CIN2. International Journal of Cancer, 2017, 140, 718-725.	2.3	19

#	Article	IF	Citations
181	Filling a gap in cervical cancer screening programmes. Lancet Oncology, The, 2014, 15, 249-251.	5.1	18
182	Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. Journal of Clinical Virology, 2014, 60, 414-417.	1.6	18
183	Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012. Journal of the National Cancer Institute, 2017, 109, .	3.0	18
184	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of Clinical Microbiology, 2018, 56, .	1.8	18
185	Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer. Cancer Causes and Control, 2020, 31, 869-879.	0.8	18
186	Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era. Ecancermedicalscience, 2015, 9, 530.	0.6	17
187	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
188	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. Journal of Infectious Diseases, 2019, 220, 1609-1619.	1.9	17
189	A prospective clinical cohort study of women at increased risk for endometrial cancer. Gynecologic Oncology, 2020, 156, 169-177.	0.6	17
190	Risk assessment to guide cervical screening strategies in a large <scp>C</scp>hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	2.3	16
191	Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes and Control, 2020, 31, 309-320.	0.8	16
192	Cervical Cancer Control in the Era of HPV Vaccination and Novel Biomarkers. Pathobiology, 2009, 76, 82-89.	1.9	15
193	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
194	The population impact of human papillomavirus/cytology cervical cotesting at 3â€year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer, 2016, 122, 3682-3686.	2.0	15
195	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
196	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	1.6	15
197	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. International Journal of Cancer, 2019, 145, 2051-2060.	2.3	15
198	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15â€year cervical cancer screening experience at Kaiser Permanente Northern California. International Journal of Cancer, 2020, 147, 1612-1620.	2.3	15

#	Article	IF	Citations
199	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
200	Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. International Journal of Oncology, 2004, 24, 987-94.	1.4	15
201	Talc Use and Ovarian Cancer: Epidemiology Between a Rock and a Hard Place. Journal of the National Cancer Institute, 2014, 106, dju260-dju260.	3.0	14
202	Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. Cancer Cytopathology, 2014, 122, 694-701.	1.4	14
203	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Womenâ€™s Health Initiative Observational Study. British Journal of Cancer, 2017, 117, 1070-1078.	2.9	14
204	Alcohol and oestrogen metabolites in postmenopausal women in the Womenâ€™s Health Initiative Observational Study. British Journal of Cancer, 2018, 118, 448-457.	2.9	14
205	Circulating inflammation markers and colorectal adenoma risk. Carcinogenesis, 2019, 40, 765-770.	1.3	14
206	Childhood Overweight, Tallness, and Growth Increase Risks of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 183-188.	1.1	14
207	Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017. American Journal of Obstetrics and Gynecology, 2021, 224, 366.e1-366.e32.	0.7	14
208	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2021, 148, 2068-2078.	2.3	14
209	Computable Guidelines and Clinical Decision Support for Cervical Cancer Screening and Management to Improve Outcomes and Health Equity. Journal of Women's Health, 2022, 31, 462-468.	1.5	14
210	Variation in NF-ÎºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
211	Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLoS ONE, 2015, 10, e0143256.	1.1	13
212	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
213	Accelerating cervical cancer control and prevention. Lancet Public Health, The, 2018, 3, e6-e7.	4.7	13
214	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Womenâ€™s Health Initiative Observational Study. Cancer Causes and Control, 2019, 30, 1201-1211.	0.8	13
215	Identification of HPV genotypes causing cervical precancer using tissueâ€based genotyping. International Journal of Cancer, 2020, 146, 2836-2844.	2.3	13
216	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13

#	Article	IF	Citations
217	Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. PLoS ONE, 2014, 9, e97045.	1.1	12
218	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. Journal of the National Cancer Institute, 2018, 110, 1222-1228.	3.0	12
219	Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathology, 2018, 126, 950-958.	1.4	12
220	Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of Ovarian Research, 2019, 12, 116.	1.3	12
221	Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix. Cancer Cytopathology, 2020, 128, 528-534.	1.4	12
222	Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence. Gynecologic Oncology, 2021, 163, 199-208.	0.6	12
223	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. Journal of the National Cancer Institute, 2022, 114, 845-853.	3.0	12
224	Redesign of a rapid, lowâ€cost <scp>HPV</scp> typing assay to support riskâ€based cervical screening and management. International Journal of Cancer, 2022, 151, 1142-1149.	2.3	12
225	Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 200-207.	1.1	11
226	Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget, 2019, 10, 2515-2529.	0.8	11
227	Genetic Variation on 9p22 Is Associated with Abnormal Ovarian Ultrasound Results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PLoS ONE, 2011, 6, e21731.	1.1	10
228	HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study. Gynecologic Oncology, 2015, 138, 94-100.	0.6	10
229	Assessment of Multifactor Geneâ€“Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
230	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	0.6	10
231	Treatment approaches for women with positive cervical screening results in low-and middle-income countries. Preventive Medicine, 2021, 144, 106439.	1.6	10
232	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers, 2021, 13, 2088.	1.7	10
233	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
234	Challenges Associated With Cervical Cancer Screening and Management in Obese Women. Journal of Lower Genital Tract Disease, 2020, 24, 184-191.	0.9	9

#	Article	IF	Citations
235	Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 636-642.	1.1	9
236	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. International Journal of Molecular Sciences, 2021, 22, 6463.	1.8	9
237	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	2.2	9
238	STRIDES - STudying Risk to Improve DisparitiES in Cervical Cancer in Mississippi â€“ Design and baseline results of a Statewide Cohort Study. Preventive Medicine, 2021, 153, 106740.	1.6	9
239	Ageâ€specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. Cancer Medicine, 2021, 10, 8641-8650.	1.3	9
240	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8
241	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.4	8
242	Cervical Cancer Screeningâ€”Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 432-434.	1.1	8
243	Tao brush endometrial cytology is a sensitive diagnostic tool for cancer and hyperplasia among women presenting to clinic with abnormal uterine bleeding. Cancer Medicine, 2021, 10, 7040-7047.	1.3	8
244	The Pill's gestation: from birth control to cancer prevention. Lancet Oncology, The, 2015, 16, 1004-1006.	5.1	7
245	Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use. Journal of Lower Genital Tract Disease, 2016, 20, 191-194.	0.9	7
246	From clinical epidemiology to practice recommendations: Knowledge gaps and uncertainty in the management of anal precancers. Cancer, 2017, 123, 4530-4534.	2.0	7
247	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. PLoS ONE, 2017, 12, e0182359.	1.1	7
248	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses, 2021, 13, 1948.	1.5	7
249	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	0.8	7
250	Population Testing for High Penetrance Genes: Are We There Yet?. Journal of the National Cancer Institute, 2018, 110, 687-689.	3.0	6
251	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
252	Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2010-2018.	1.1	6

#	Article	IF	Citations
253	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	1.1	6
254	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	1.3	6
255	Quantifying procedural pain associated with office gynecologic tract sampling methods. Gynecologic Oncology, 2021, 162, 128-133.	0.6	6
256	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 75, 1565-1572.	2.9	6
257	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. Journal of Lower Genital Tract Disease, 2018, 22, 97-103.	0.9	5
258	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	2.3	5
259	Genome-Wide Geneâ€“Diabetes and Geneâ€“Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	1.1	5
260	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.4	5
261	Trends in hysterectomyâ€corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?. International Journal of Cancer, 2021, 148, 584-592.	2.3	5
262	Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3). International Journal of Epidemiology, 2022, 51, e73-e86.	0.9	5
263	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
264	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. Cancer Prevention Research, 2021, 14, 919-926.	0.7	5
265	Different human papillomavirus types share early natural history transitions in immunocompetent women. International Journal of Cancer, 2022, 151, 920-929.	2.3	5
266	Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register. Gynecologic Oncology, 2018, 148, 547-552.	0.6	4
267	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. Statistics in Medicine, 2020, 39, 4405-4420.	0.8	4
268	Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies. International Journal of Cancer, 2021, 148, 2692-2701.	2.3	4
269	Liquid Biopsy for Cancer Detection: Clinical and Epidemiologic Considerations. Clinical Cancer Research, 2021, 27, 5733-5735.	3.2	4
270	Multisite Clinical Validation of Isothermal Amplification-Based SARS-CoV-2 Detection Assays Using Different Sampling Strategies. Microbiology Spectrum, 2021, 9, e0084621.	1.2	4

#	Article	IF	Citations
271	Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes and Control, 2017, 28, 429-435.	0.8	3
272	Distribution of cell types differs in Papanicolaou tests of squamous cell carcinomas and adenocarcinomas. Journal of the American Society of Cytopathology, 2017, 6, 10-15.	0.2	3
273	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
274	The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 231-233.	3.0	3
275	Cervical Screening Performance. American Journal of Clinical Pathology, 2021, 155, 616-620.	0.4	3
276	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. Gynecologic Oncology, 2021, 161, 297-303.	0.6	3
277	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
278	Development of a Large Biorepository of Cervical Specimens for theImproving Risk Informed HPV Screening Study (IRIS). Journal of Clinical Virology, 2021, 145, 105014.	1.6	2
279	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
280	Towards therapeutic vaccination against cervical precancer?. Lancet, The, 2015, 386, 2036-2038.	6.3	1
281	Hidden moverâ€stayer model for disease progression accounting for misclassified and partially observed diagnostic tests: Application to the natural history of human papillomavirus and cervical precancer. Statistics in Medicine, 2021, 40, 3460-3476.	0.8	1
282	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	1.1	1
283	Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the prostate, lung, colorectal and ovarian cancer screening trial.. Annals of Epidemiology, 2022, 68, 1-8.	0.9	1
284	Using Natural Language Processing to Improve Discrete Data Capture From Interpretive Cervical Biopsy Diagnoses at a Large Health Care Organization. Archives of Pathology and Laboratory Medicine, 2023, 147, 222-226.	1.2	1
285	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	0
286	Reply to HPV test results provide useful risk stratification information in women with ASCâ€H Pap test findings. Cancer Cytopathology, 2016, 124, 754-755.	1.4	0
287	Response. Journal of the National Cancer Institute, 2016, 108, djv390.	3.0	0
288	In Defense of a Simplified, Practical Colposcopic Terminology. Journal of Lower Genital Tract Disease, 2018, 22, 233-234.	0.9	0

#	Article	IF	Citations
289	Response to Pretorius and Belinson. Journal of the National Cancer Institute, 2020, 112, 115-116.	3.0	0
290	Genital Powder Use and Ovarian Cancerâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 323, 2096.	3.8	0
291	What Contributes to Pregnancy Complications Among Women With Cervical Intraepithelial Neoplasia Grade 3?. Annals of Internal Medicine, 2022, 175, 293-294.	2.0	0
292	Reply to: Comments on â€œMetaâ€analysis of agreement/concordance statistics in studies comparing selfâ€• vs clinicianâ€collected samples for HPV testing in cervical cancer screeningâ€• International Journal of Cancer, 2022, 151, 484-487.	2.3	0